Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study

• Main Authors: Hongxin Li (Author), Wen Zhao (Author), Caiyun Chang (Author), Tiantian Xuan (Author), Chengjun Wang (Author), Rongyu Zhang (Author), Chuang Yang (Author), Jian Wang (Author), Cuihua Yi (Author), Xiuwen Wang (Author), Shuwen Yu (Author), Jisheng Li (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundAumolertinib demonstrated superior progression-free survival (PFS) and a well-tolerated toxicity profile compared to gefitinib in front-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in the AENEAS trial. However, patient-reported outcomes (PROs) of aumo...